Ovarian Cancer

Ursula A. Matulonis, MD, professor of Medicine, Harvard Medical School, medical director of Gynecologic Oncology, Dana-Farber Cancer Institute, discusses toxicities associated with PARP inhibitors in ovarian cancer.

Patients with proliferative or mesenchymal ovarian tumors treated with bevacizumab (Avastin) had superior progression-free survival and a trend toward improved overall survival compared with patients with immunoreactive or differentiated tumors.

Dennis Scribner, MD, discusses the treatment landscape for patients with recurrent ovarian cancer and how PARP inhibitors have enhanced the treatment options for this population.

Adding bevacizumab to standard platinum-based chemotherapy was associated with a clinically significant improvement in median overall survival in women with recurrent ovarian cancer.

Preclinical findings showed that the combination of the investigational agent birinapant and carboplatin could eliminate platinum-resistant, high-grade serous carcinoma ovarian tumor cells.

Franco M. Muggia, MD, PhD, professor, Department of Medicine, NYU Langone Medical Center, discusses targeted therapies for patients with ovarian cancer.

Within the last 30 days of life, black and Latina women with ovarian cancer were less likely than white women to enroll in hospice care, according to results recently published in the Journal of Clinical Oncology.

Bradley J. Monk, MD, shares his insight on the potential of immunotherapy in ovarian cancer, as well as what promise it might hold in other gynecologic malignancies.

Ursula A. Matulonis, MD, professor of Medicine, Harvard Medical School, medical director of Gynecologic Oncology, Dana-Farber Cancer Institute, discusses maintenance therapy in ovarian cancer.

Emma Barber, MD, UNC Department of Obstetrics and Gynecology, UNC School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses neoadjuvant chemotherapy versus surgery for patients with ovarian cancer.

Dana M. Chase, MD, FACOG, an associate professor at Creighton University, University of Arizona College of Medicine, and gynecologist oncologist with Arizona Oncology, discusses the toxicity profiles and managing side effects of treatments for patients with recurrent ovarian cancer.

Lyndsay J. Willmott, MD, highlights the FDA-approved PARP inhibitors for ovarian cancer and how these approvals have impacted clinical practice.

Mike Janicek, MD sheds light on why physicians are slow to educate patients on testing, the detection of genes aside from BRCA1/2, and the lesser-known benefits of getting genetic testing early on in a diagnosis.

Dana Chase, MD, expands on the pivotal clinical trials, managing toxicities, and the questions researchers still need to answer regarding bevacizumab for patients with ovarian cancer.

Heather Dalton, MD, discusses the first-line treatment options currently available for patients with ovarian cancer, pivotal data that have solidified standard approaches, and why chemotherapy will likely always remain critical in the ovarian cancer sphere.

Shana Wingo, MD, explains how surgical approaches have evolved in ovarian cancer.

Treatment with the RAF dimer inhibitor BGB-283 led to clinical benefit for patients with BRAF V600-mutated melanoma, papillary thyroid cancer, and ovarian cancer.

Ursula A. Matulonis, MD, discusses the latest regulatory advances with PARP inhibitors and their continued growth in the treatment of patients with ovarian cancer.

Paul Pharoah, MD, PhD, discusses the significance of his research in ovarian cancer and the potential for translating genetic discoveries into meaningful clinical benefits.

The FDA has granted a priority review to a new drug application for olaparib (Lynparza) as a maintenance therapy in relapsed patients with platinum-sensitive ovarian cancer, according to AstraZeneca, the manufacturer of the PARP inhibitor.

The FDA has approved the PARP inhibitor niraparib (Zejula) for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.

Emma Barber, MD, discusses the impact of neoadjuvant chemotherapy on readmission rates, and how the goal of lowering readmission rates in ovarian cancer may not always align with optimizing long-term outcomes.